This Journal feature begins with a case vignette highlightinga common clinical problem. Evidence supporting various strategiesis then presented, followed by a review of formal guidelines,when they exist. The article ends with the authors' clinicalrecommendations.
A 63-year-old man underwent complete resection of a T3N0M0,stage II adenocarcinoma of the ascending colon. No adjuvanttherapy is planned. There is no family history of colorectalcancer. How should he be followed?
The Clinical Problem
Colorectal adenocarcinoma is the second leading cause of deathdue to cancer in the United States, accounting for more than50,000 deaths annually.1 Surgery is the cornerstone of . . . [Full Text of this Article]
Strategies and Evidence
Areas of Uncertainty
Specific Surveillance Tests
Other Uncertainties
Guidelines
Conclusions and Recommendations
Source Information
From the Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York (D.G.P.); the Division of HematologyOncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago (A.B.B.); and the Cancer Policy and Clinical Affairs Department, American Society of Clinical Oncology, Alexandria, Va. (M.R.S.).
Address reprint requests to Dr. Pfister at Memorial Hospital, Box 188, 1275 York Ave., New York, NY 10021, or at pfisterd@mskcc.org.
This article has been cited by other articles:
Van Cutsem, E., Oliveira, J., On behalf of the ESMO Guidelines Working Group,
(2009). Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol
20: iv49-iv50
[Full Text]
Wang, G., Haile, S., Comuzzi, B., Tien, A. H., Wang, J., Yong, T. M.K., Jelescu-Bodos, A. E., Blaszczyk, N., Vessella, R. L., Masri, B. A., Sadar, M. D.
(2009). Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression. Cancer Res.
69: 3433-3442
[Abstract][Full Text]
FREDERIKSEN, C., LOMHOLT, A.F., DAVIS, G.J., DOWELL, B.L., BLANKENSTEIN, M.A., CHRISTENSEN, I.J., BRUNNER, N., NIELSEN, H.J.
(2009). Changes in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer. Anticancer Res
29: 75-81
[Abstract][Full Text]
Yang, W., Luo, D., Wang, S., Wang, R., Chen, R., Liu, Y., Zhu, T., Ma, X., Liu, R., Xu, G., Meng, L., Lu, Y., Zhou, J., Ma, D.
(2008). TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis. Clin. Cancer Res.
14: 5494-5502
[Abstract][Full Text]
Rodriguez-Moranta, F., Salo, J., Arcusa, A., Boadas, J., Pinol, V., Bessa, X., Batiste-Alentorn, E., Lacy, A. M., Delgado, S., Maurel, J., Pique, J. M., Castells, A.
(2006). Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial. JCO
24: 386-393
[Abstract][Full Text]
Goldberg, R. M.
(2006). Intensive Surveillance After Stage II or III Colorectal Cancer: Is It Worth It?. JCO
24: 330-331
[Full Text]
Lee, J.-C., Lee, C.-H., Su, C.-L., Huang, C.-W., Liu, H.-S., Lin, C.-N., Won, S.-J.
(2005). Justicidin A decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cells. Carcinogenesis
26: 1716-1730
[Abstract][Full Text]
Keating, N. L., Landrum, M. B., Meara, E., Ganz, P. A., Guadagnoli, E.
(2005). Do Increases in the Market Share of Managed Care Influence Quality of Cancer Care in the Fee-For-Service Sector?. JNCI J Natl Cancer Inst
97: 257-264
[Abstract][Full Text]